

Living Cell Technologies Ltd

PO Box 3014, Auburn VIC 3123

ABN: 14 104 028 042



LCT CEO to present at International LARTA Venture Forum

ASX Announcement – 1 May, 2007

Dr Paul Tan, CEO of Living Cell Technologies Ltd and Mr Richard Justice, CFO, will be presenting at The Venture Forum 2007 in San Francisco on 1 May 2007.

The conference is held by the Larta Institute. LCT was selected after a rigorous selection process amongst companies across different fields. LCT is one of only five New Zealand companies attending and supported by the New Zealand government agency Foundation for Research Science & Technology.

The Venture Forum has been running for 13 years and is the largest showcase of early stage innovation and entrepreneurship.

Involvement in the program has provided LCT with commercial mentoring workshops with international business and commercialisation advisors, as well as assistance in securing high-level meetings with potential licensing partners and investors in the US.

Dr Tan will provide a presentation outlining LCT's capabilities in the xenotransplantation field, as well as an update of the clinical trial program.

Dr Tan and Mr Justice will also be making a number of investor presentations in New York, San Francisco and London during the trip.

A copy of the Venture Forum presentation is attached.

Further information:		
Paul Tan CEO Mob: +64 21 608 784	Richard Justice CFO Mob: +64 27 222 3806	Paris Brooke General Manager Mob: +61 407 715 574

About Living Cell Technologies: www.lctglobal.com

Living Cell Technologies Ltd (ASX: LCT) develops live cell therapy products to treat life threatening human diseases. The ASX listed, vertically integrated company focuses on treatments for people with insulin-dependent diabetes and neurological disorders. The company owns a specialised biocertified pig herd for a safe, reliable source of cells for treatment.



**World First Company
Implementing Xenotherapy
Complying with Present Day Safeguards**

**The VENTURE FORUM 2007
San Francisco**

**Dr Paul Tan, CEO
Mr Richard Justice, CFO**

LEADING XENO-CELL THERAPY
15 years R&D
ASX listed public company

Lead Product

Alginate encapsulated neonatal pig islets

Indication

Type 1 diabetes

1% market penetration = \$370M pa

*Competitive
Advantage*

No immunosuppression

Safety data

Long term functioning graft

Integrated capabilities to meet
regulatory requirements

Stage

Human clinical trials in 2007

internationally reviewed

NZ regulatory approval




Critical Success Factors

First vertically integrated cell therapy company

- Fully owned exclusive biocertified pig herd
- GMP cell supply for clinic
- Accredited xeno-diagnostic laboratory
- Patents: neonatal pig cells and alginate

LCT in phase for growth in value

- Requiring capital investments
- Technologies for licensing and
- Supply of Biocert^R pigs



Essential Capabilities -1 Sub-Antarctic Pig Herd

Exclusive source of **high health status pigs**: US FDA Guidelines 2003

- Absence of xeno-relevant viruses, bacteria and parasites
- Does not secrete pig endogenous retroviruses
- A closed herd bred in isolation (across 2 facilities): 3 yr health records and regular monitoring
- Three generations without mammalian content in feed



Auckland Islands - NZ



LCT Designated-Pathogen-Free Pig Breeding Facility
Fully owned and exclusive supply of pigs

Essential Capabilities - 2 Accreditation for Product

Pilot Manufacturing Plant

Over 15 years, LCT has developed quality controlled encapsulated neonatal pig islets

- GMP certification in New Zealand xeno product for human medical use
- Product development supported by NZ government agencies

Foundation for Research, Science & Technology
NZ Trade & Enterprise



Monitoring of Recipients Post Transplant: safety


- Although no pig to human infection in 20+ years of xenotransplantation - monitoring is a regulatory requirement.
- LCT has a panel of tests and protocols for monitoring recipients in accredited laboratories: audited by International Accreditation NZ
- Published 9 year safety data: monitoring of pig cell recipients

Implant Functioning at 10 years

Case Report published in *Xenotransplantation*, March 2007

- 1996 implant of prototype product in abdomen of type 1 diabetes patient
- Patient showed long term clinical improvement
- In 2005-6, biopsy shows live islet cells and pig insulin detected in blood
- Longest reported survival and function of cell implant without immunosuppression

1996 implantation



2005 Laparoscopy and biopsy



Company Value and Products in Development:

NeurotrophinCell

(Huntington's disease, Stroke, Hearing loss)

Pre-clinical phase

Fac8Cell

(Haemophilia) Research phase

Pig tissues

(Heart valves, collagen, tendons etc.)

Market ready

Each piglet potentially offers:

5 neuro patients


1/6 diabetes patient

1 liver patient

? hearing-impaired patients ...

? Tissues, biomaterials & biologicals.....

Significant revenue per piglet



Current Commercial Imperatives

LCT's business model for the US

1: Clinical Trials in Type 1 Diabetes

- Phase I/IIA clinical trials in New Zealand
- Take Phase I/IIA data to US FDA in 2008-9 for development

2: Capital Raising & Revenue Generation

- Capital Investments for clinical program
- Licensing DiabeCell in Phase I/IIa, NeurotrophinCell in pre-clinical linked with supply of BioCert® pigs
- Licensing BioCert® Pigs for biomaterials

3: Developing LCT products in US

- Funds to develop DiabeCell in US
- Managed growth of corporate and commercial expertise in US



New Zealand – Auckland, Invercargill

Pig Breeding, GMP manufacturing,
Clinical Trial, R&D

Australia – Sydney, Melbourne

Corporate, Investor Relations

USA – Rhode Island

Materials Qualification and Regulatory

Italy – Perugia

Materials Development

Accessing World-Class Capabilities

Dr Paul Tan, CEO

13 years in biotechnology operations, product development, international clinical trials, patent management, physician-investigator Auckland University

Richard Justice, CFO

Accountant with business management background, international public listing experience in NZ, Australia, Canada, USA

Professor Bob Elliott, Medical Director

Paediatrician- investigator, 20 years research in diabetes, Emeritus Professor University of Auckland.

Paris Brooke, General Manager

Business positioning, investor and media relations in biotechnology industry

www.lctglobal.com

without geographical boundaries

LCT is a leading xeno cell therapy company

15 years research and development

World First vertically integrated cell therapy company

- Fully owned exclusive biocertified pig herd
- GMP cell manufacturing
- Accredited xeno-diagnostic laboratory
- Patents: neonatal pig cells and alginate specifications

World First human clinical trials with current regulations

- Approval from NZ and international reviewers
- Near product commercialisation

LCT poised for growth in value

- Requiring investments – US\$12m for Phase I/IIA
- Licensing technologies
- Supply of Biocert^R pigs

